Inebilizumab for type 1 autoimmune pancreatitis
Treatments studied
Part of Digestive system, Immune system & allergy clinical trials.
This trial tests a new treatment called inebilizumab for type 1 autoimmune pancreatitis, a condition where the immune system attacks the pancreas. The goal is to see if this treatment can reduce symptoms and prevent damage to the pancreas and other organs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with type 1 autoimmune pancreatitis.
- You have symptoms like jaundice, abdominal pain, or back pain, or have evidence of pancreas or bile duct involvement, or you have no symptoms but tests show a risk of serious organ damage.
- You are willing to take oral medication and follow the study schedule.
- If you are a woman who can have children, you must agree to use contraception during the study.
- You do not have conditions that would exclude you, such as active infections, cancer, or severe heart or breathing problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a treatment to prevent recurrence in people with type 1 autoimmune pancreatitis (AIP) who are at high risk. It looks at how well the treatment works and whether it can keep the disease from coming back.
This trial is testing an oral medication called ivarmacitinib, which may help protect the insulin-making cells in your pancreas and slow down the progression of type 1 diabetes. It is designed for people who have just been diagnosed with type 1 diabetes.
This study tests a new drug called IBI343 compared to a placebo (inactive substance) for people with advanced pancreatic cancer that has a specific protein (CLDN18.2) and has not responded to earlier treatments. The goal is to see if IBI343 can help slow the cancer's growth.
This study tests a new biologic medicine called inebilizumab that may help people whose autoimmune hepatitis hasn't improved with standard treatments. The goal is to see if it can reduce liver inflammation and improve their condition.
This study tests a drug called inebilizumab in children and teens with IgG4-related disease, a rare condition causing swelling and organ damage. The drug may help reduce the immune system attack that causes the disease. It may be an option if standard treatments haven't fully worked.
This study tests a new medicine called inebilizumab for people with primary membranous nephropathy, a kidney disease. The medicine may help reduce protein in the urine and protect kidney function.
Hear when a new Type 1 AIP trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.